Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Arcturus Therapeutics Holdings Inc (ARCT) under the Base Case is 3.98 USD per share.
Compared with the current market price of 8.36 USD, the stock appears
Overvalued by 52% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Arcturus Therapeutics Does
Arcturus Therapeutics develops RNA medicines and vaccines. It designs messenger RNA and self-amplifying RNA drugs that tell the body’s cells to make a specific protein, then packages that RNA inside lipid nanoparticles so it can be delivered into the body. The company’s main work is in infectious disease vaccines and treatments for rare liver and genetic diseases.
- Headquarters
- United States of America US
- Employees
- 106
- IPO date
- May 22, 2013
Revenue & Expenses Breakdown
Arcturus Therapeutics Holdings Inc
Earnings Waterfall
Arcturus Therapeutics Holdings Inc
Continue ARCT Research
Decided on Arcturus Therapeutics Holdings? Get an email when ARCT reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one ARCT stock?
The intrinsic value for
Arcturus Therapeutics Holdings Inc (ARCT) under the Base Case is 3.98 USD.
Is ARCT stock undervalued or overvalued?
Compared with the current market price of 8.36 USD, the stock appears Overvalued by 52% .